[HTML][HTML] Artificial intelligence in pharmaceutical technology and drug delivery design

LK Vora, AD Gholap, K Jetha, RRS Thakur, HK Solanki… - Pharmaceutics, 2023 - mdpi.com
Artificial intelligence (AI) has emerged as a powerful tool that harnesses anthropomorphic
knowledge and provides expedited solutions to complex challenges. Remarkable …

Protein subunit vaccines: Promising frontiers against COVID-19

VP Chavda, ENHK Ghali, PC Balar… - Journal of Controlled …, 2024 - Elsevier
The emergence of COVID-19 has posed an unprecedented global health crisis, challenging
the healthcare systems worldwide. Amidst the rapid development of several vaccine …

Hyperimmune Plasma and Immunoglobulins against COVID-19: a narrative review

M Franchini, D Focosi - Life, 2024 - mdpi.com
Since late 2019, the new SARS-CoV-2 virus belonging to the Coronaviridae family has been
responsible for COVID-19 pandemic, a severe acute respiratory syndrome. Several antiviral …

SARS‐CoV‐2 neutralising antibody therapies: Recent advances and future challenges

M Liu, Z Liang, ZJ Cheng, L Liu, Q Liu… - Reviews in Medical …, 2023 - Wiley Online Library
The COVID‐19 pandemic represents an unparalleled global public health crisis. Despite
concerted research endeavours, the repertoire of effective treatment options remains limited …

[PDF][PDF] Artificial Intelligence in Pharmaceutical Technology and Drug Delivery Design. Pharmaceutics. 2023; 15: 1916

LK Vora, AD Gholap, K Jetha, RRS Thakur, HK Solanki… - 2023 - digitalrosh.com
Artificial intelligence (AI) has emerged as a powerful tool that harnesses anthropomorphic
knowledge and provides expedited solutions to complex challenges. Remarkable …

Blood filtering system for COVID-19 management: novel modality of the cytokine storm therapeutics

VP Chavda, N Raval, S Sheta, LK Vora… - Frontiers in …, 2023 - frontiersin.org
The newly emerged coronavirus (SARS-CoV-2) is virulent, contagious, and has rapidly
gained many mutations, which makes it highly infectious and swiftly transmissible around …

[HTML][HTML] Next-generation treatments: Immunotherapy and advanced therapies for COVID-19

JA Arevalo-Romero, SM Chingaté-López, BA Camacho… - Heliyon, 2024 - cell.com
The COVID-19 pandemic, caused by severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2), emerged in 2019 following prior outbreaks of coronaviruses like SARS and …

Regulatory processes involved in clinical trials and intellectual property rights around vaccine development

N Desai, S Pande, AD Gholap, D Rana… - … for Infectious and …, 2024 - Elsevier
This chapter explores the critical intersection of regulatory processes and intellectual
property rights (IPR) within the context of vaccine development. With the ongoing global …

Evaluation of Neutralizing Capacity of Tixagevimab plus Cilgavimab (AZD7442) against Different SARS‐CoV‐2 Variants: A Case Report Study with Comparison to a …

C Gillot, JL Bayart, V Maloteau… - Case reports in …, 2024 - Wiley Online Library
AZD7442 (150 mg of tixagevimab plus 150 mg of cilgavimab) has been approved for the
preexposure prophylaxis of COVID‐19 and for the treatment of adults and adolescents with …

Harnessing Antiviral Peptides as Means for SARS-CoV-2 Control

K Zarkesh, M Akbarian, L Tayebi, VN Uversky… - COVID, 2023 - mdpi.com
Several times during the past two decades, epidemic viral diseases created global
challenges. Although many solutions have been proposed to deal with this tight spot, it is still …